These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36706956)

  • 21. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
    Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
    J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
    Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
    Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
    Dunlap NE; Yang W; McIntosh A; Sheng K; Benedict SH; Read PW; Larner JM
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1071-7. PubMed ID: 22898383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
    Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy.
    Takeda K; Takanami K; Shirata Y; Yamamoto T; Takahashi N; Ito K; Takase K; Jingu K
    J Radiat Res; 2017 Nov; 58(6):862-869. PubMed ID: 29036692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial.
    Askoxylakis V; Dinkel J; Eichinger M; Stieltjes B; Sommer G; Strauss LG; Dimitrakopoulou-Strauss A; Kopp-Schneider A; Haberkorn U; Huber PE; Bischof M; Debus J; Thieke C
    Radiat Oncol; 2012 Sep; 7():157. PubMed ID: 22974533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
    Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
    Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
    Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
    J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment
    Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.
    Essler M; Wantke J; Mayer B; Scheidhauer K; Bundschuh RA; Haller B; Astner ST; Molls M; Andratschke N
    Strahlenther Onkol; 2013 Jun; 189(6):495-501. PubMed ID: 23609133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
    Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
    Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
    Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid
    Yang DM; Palma D; Louie A; Malthaner R; Fortin D; Rodrigues G; Yaremko B; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):94-101. PubMed ID: 30281918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
    Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
    Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [
    Yang DM; Palma DA; Kwan K; Louie AV; Malthaner R; Fortin D; Rodrigues GB; Yaremko BP; Laba J; Gaede S; Warner A; Inculet R; Lee TY
    Radiat Oncol; 2021 Jan; 16(1):11. PubMed ID: 33441162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.